Wibi+Works Therapeutics

Wibi+Works Therapeutics takes adult mesenchymal stem cells (MSC), already recognized for their safety, usefulness, and effectiveness, and makes them better. Wibi+Works is evaluating antimunocel™, an anti-inflammatory MSC-based therapy targeted for the treatment of inflammatory diseases like, IBD, RA, MS, and pain. We are also developing proimunocel™, a new type of cancer immunotherapy, that safely and effectively kills the cancer cells while simultaneously reawakening the host's anti-tumor immunity. We have successfully tested our cell therapies in over 7 preclinical disease models. The technology has been validated by others and with MSCs from various adult tissue sources like bone marrow and fat.